Targeted therapy: Sunitinib modulates MCL-1 and mTOR signalling


Despite improvements in overall survival being achieved with the use of targeted therapies, the onset of resistance to treatment is virtually inevitable. In a translational study, researchers demonstrated enhanced stability of the antiapoptotic protein MCL-1, which resulted in an increase in mTORC1 activity in cancer cells exposed to clinically relevant… (More)
DOI: 10.1038/nrclinonc.2016.208


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics